Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.

RU58841 is being discussed as a hair loss treatment without using finasteride or dutasteride. Users are sharing their experiences and success with RU58841 alone.

A user's journey to treat hair loss with a combination of oral medication, topical treatments, microneedling and different shampoos and supplements. It includes warnings about an OGX biotin shampoo potentially causing further hair loss.

The user is using a hair loss treatment regimen including Avodart (dutasteride), oral minoxidil, LLLT caps, vitamins, and ketoconazole shampoo, and is considering adding dermarolling and RU58841. They are experiencing unwanted body hair growth from minoxidil and are planning for a future hair transplant.

User got a hair system after hair transplant and finasteride didn't meet their needs. Hair system cost $200, initial install $150, and user is satisfied with the results.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

A user shared their experience with a 7600 graft hair transplant using scalp, beard, and chest hair over three procedures, expressing satisfaction with the results despite mixed feedback. They also used finasteride to thicken hair and considered scalp micropigmentation for further improvement.

The user discusses using finasteride (1mg every other day) and topical minoxidil once a day for hair regrowth over 90 days. They are inquiring about the effectiveness of this treatment for hair regrowth.

A user's extreme regimen for hair loss, which includes taking oral and topical medications such as minoxidil, dutasteride, cyproterone acetate and bicalutamide, but still experiencing miniaturization. Suggestions were made to try other treatments such as RU58841 and Pyrilutamide, while also considering mental health treatment and advice on lookmaxxing.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

GHK-Cu is being discussed as a potential treatment for male pattern baldness. Users are sharing experiences and asking about its effectiveness and side effects.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

A 26-year-old male is documenting his hair regrowth journey using 0.5mg dutasteride and 5mg oral minoxidil, transitioning from 5% topical minoxidil. He reports no significant side effects after one week, except for slight water retention and increased libido.

The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.

The user has experienced limited hair regrowth using 1mg oral finasteride, topical minoxidil foam, and occasional dermarolling since August 2023. They are considering switching to dutasteride, adding oral minoxidil 2.5 mg, and RU58841 to improve results.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

LLLT (low-level laser therapy) is as effective or better than traditional minoxidil treatment for hair growth, with fewer side effects and improved long-term compliance due to milder adverse effects. Studies show LLLT increases hair density more than minoxidil, but drawbacks include the initial cost and the need for long-term use to see results.

A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

User asked dermatologist for finasteride, received latanoprost and diprogenta cream instead. Others suggest latanoprost is expensive and not better than minoxidil, recommend trying another doctor for finasteride.

The user is sharing their experience with using 0.5mg dutasteride, 2.5mg oral minoxidil, and hair dye for 45 days. Another user encourages them to continue as it is still too early to see significant improvement.

Winlevi is being discussed as a potential treatment for hair loss. Users are sharing their experiences with Minoxidil, finasteride, and RU58841.